Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Raal, Frederick J., Kallend, David, Ray, Kausik K., Turner, Traci, Koenig, Wolfgang, Wright, R. Scott, Wijngaard, Peter L.J., Curcio, Danielle, Jaros, Mark J., Leiter, Lawrence A., Kastelein, John J.P.·2020·New England Journal of Medicine
DOI 10.1056/nejmoa1913805

Cited by (820)

Items 401–500 of 820

  1. A Convenient Oligonucleotide Conjugation via Tandem Staudinger Reaction and Amide Bond Formation at the Internucleotidic Phosphate Position
    Kristina Klabenkova, Polina V. Zhdanova, Ekaterina A. Burakova, S.N. Bizyaev, А. А. Фокина, Dmitry A. Stetsenko · 2024 · International Journal of Molecular Sciences
  2. Safety and efficacy of inclisiran in treating hypercholesterolemia: A systemic review and meta-analysis
    Zhiling Cheng, Meiling Gao, Yang Liu, Wei Yan, Zhihan Zhang, Ning Jiao, Congxin Li · 2024 · Nutrition Metabolism and Cardiovascular Diseases
  3. Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta‐Analysis of Randomised Controlled Trials
    Jawad Basit, Mushood Ahmed, Priyansha Singh, Areeba Ahsan, Eeshal Zulfiqar, Javed Iqbal, Maurish Fatima, Prakash Upreti, Mohammad Hamza, M. Chadi Alraies · 2025 · Endocrinology Diabetes & Metabolism
  4. Efficacy and safety of inclisiran based on background lipid-lowering treatment
    Ulf Landmesser, Wolfgang Köenig, Lawrence A. Leiter, Frederick Johan Raal, Kausik Kumar Ray, Gregory G. Schwartz, Jackie Han, Lorena Garcia Conde, R Scott Wright · 2025 · European Journal of Preventive Cardiology
  5. Gene therapy for cardiac arrhythmias
    Sahej Bains, John R. Giudicessi, Katja E. Odening, Michael Ackerman · 2025 · Nature Reviews Cardiology
  6. Lipoprotein(a) and Cardiovascular Risk in Asian Populations: A Comprehensive Review
    Jung A Kim, Nam Hoon Kim · 2025 · Journal of Lipid and Atherosclerosis
  7. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: Role as a promising approach
    Zheng, Xiaoxiao, Yuan, Wei, Li, Ling, Ma, Hongyue, Zhu, Mingxia, Li, Xiuli, Feng, Xinhong · 2025 · European Journal of Medical Research
  8. Unlocking the regulatory code of RNA: launching the Human RNome Project
    Mark D. Adams, Etienne Boileau, Janusz Marek Bujnicki, Vivian G. Cheung, Silvestro Giovanni Conticello, Peter C. Dedon, Christoph Dieterich, Angela Gallo, Jonathan Göke, Mark Helm et al. · 2025 · Genome biology
  9. Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy
    Brian Tomlinson, Paul Chan, Yuzhen Zhang, Christopher Wai Kei Lam · 2020 · Expert Opinion on Pharmacotherapy
  10. Lipoprotein(a): a Case for Universal Screening in Youth
    Aparna Alankar, Preneet Cheema Brar, Brenda Kohn · 2023 · Current Atherosclerosis Reports
  11. Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys
    Dario E. Lehoux, Adel Rafai Far, David G. Kallend, Peter L. J. Wijngaard, Brad R. Zerler · 2022 · Toxicology and Applied Pharmacology
  12. Familial Hypercholesterolemia Among Young Adults With Acute Coronary Syndrome
    Feras Haskiah, Daniel Erez, Abid Khaskia · 2022 · The American Journal of Cardiology
  13. LDL-C–Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes
    Raul Dias Santos, Marina Cuchel · 2024 · Circulation
  14. New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing
    Rai Ajit K. Srivastava · 2023 · Nutrition Metabolism and Cardiovascular Diseases
  15. A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022
    Qin Luo, Zhenchu Tang, Panyun Wu, Zhangling Chen, Zhenfei Fang, Fei Luo · 2023 · Frontiers in Endocrinology
  16. Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future
    Mohammed Ali Faluk, Abdirahman Wardhere, Abdilahi A. Mohamoud, Mohammed A Nor, Dimitrios Bampastsias, Ermioni Oikonomou, Zaid Almubaid, Bashar Al Hemyari · 2024 · Current Problems in Cardiology
  17. Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database
    Giuseppe Cicala, Michelangelo Rottura, Viviana Maria Gianguzzo, Federica Cristiano, Selene Francesca Anna Drago, Giovanni Pallio, Natasha Irrera, Egidio Imbalzano, Edoardo Spina, Vincenzo Arcoraci · 2024 · Pharmaceuticals
  18. New Approaches to Lipoproteins for the Prevention of Cardiovascular Events
    Masashi Fujino, Giuseppe Di Giovanni, Stephen James Nicholls · 2024 · Journal of Atherosclerosis and Thrombosis
  19. Exosomes and non-coding RNAs: Exploring their roles in human myocardial dysfunction
    Magdalena Kulus, Maryam Farzaneh, Mohadeseh Sheykhi-Sabzehpoush, Farhoodeh Ghaedrahmati, Fatemeh Mehravar, Małgorzata Józkowiak, Hanna Piotrowska‐Kempisty, Dorota Bukowska, Paweł Antosik, Marzenna Podhorska‐Okołów et al. · 2025 · Biomedicine & Pharmacotherapy
  20. Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
    Ежов Марат Владиславович, Valery V. Kukharchuk, Т. В. Балахонова, Victor S. Gurevich, И. В. Сергиенко, Alexey A. Sokolov, Семенкин Александр Анатольевич, Шапошник Игорь Иосифович, Н. М. Ахмеджанов, О. Л. Барбараш et al. · 2025 · Eurasian heart journal
  21. Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening: The VICTORION-PLAQUE primary prevention trial
    Pruthvi C. Revaiah, Patrick W.J.C. Serruys, Yoshinobu Onuma, Daniele Andreini, Matthew Jay Budoff, Faisal Sharif, Ariel Chernofsky, Sheikh Vikarunnessa, Andrea J. Wiethoff, Denise P. Yates et al. · 2025 · American Heart Journal
  22. Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications
    Mariana Becker Pfeferman, Sina Rashedi, Gregory Y.H. Lip, Christian Weber, Michelle L. O’Donoghue, Steven E. Nissen, Stephen James Nicholls, Pradeep Natarajan, Jorge Plutzky, Peter Libby et al. · 2025 · Thrombosis and Haemostasis
  23. Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials
    Martin D. Mulligan, Rahul S Gandhi, Rishabh Vishwakarma, Romit Bhattacharya · 2026 · Journal of clinical lipidology
  24. Dyslipidemia
    Alan P. Jacobsen, Seamus Paul Whelton, Roger Scott Blumenthal, John William McEvoy · 2023 · Elsevier eBooks
  25. Beyond Statins: Novel Lipid-Lowering Agents for Reducing Risk of Atherosclerotic Cardiovascular Disease
    Teimur Kayani, Bachar Ahmad, Rachel Chang, Frank Qian, Melis Sahinoz, Muhammad Rehan, Antonio Giaimo, Erica Sarah Spatz, Jiun‐Ruey Hu · 2024 · Pharmacoepidemiology
  26. Emerging roles of PCSK9 in kidney disease: lipid metabolism, megalin regulation and proteinuria
    Sandra Hummelgaard, Jean‐Claude Kresse, Michael Schou Jensen, Simon Glerup, Kathrin Weyer · 2025 · Pflügers Archiv - European Journal of Physiology
  27. Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias
    Fabiana Hanna Rached, Raul Dias Santos · 2021 · Current Cardiology Reports
  28. NICE guidance on inclisiran should be reconsidered
    Paula Byrne, Maryanne Demasi, Susan M. Smith · 2021 · BMJ
  29. Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin
    Felix Sebastian Nettersheim, Felix S.R. Picard, Friedrich Felix Hoyer, Holger Winkels · 2022 · Frontiers in Cardiovascular Medicine
  30. (Pro)renin receptor inhibition attenuated liver steatosis, inflammation, and fibrosis in mice with steatohepatitis
    Yun‐Cheng Hsieh, Pei‐Shan Wu, Yi-Tsung Lin, Yi‐Hsiang Huang, Ming‐Chih Hou, Kuei‐Chuan Lee, Han‐Chieh Lin · 2022 · The FASEB Journal
  31. Perioperative Management and Clinical Outcomes of Liver Transplantation for Children with Homozygous Familial Hypercholesterolemia
    Huanrong Qiu, Liang Zhang, Zhi‐Jun Zhu · 2022 · Medicina
  32. Innate Immunity in Cardiovascular Diseases—Identification of Novel Molecular Players and Targets
    Wolfgang C. Poller, Bettina Heidecker, Enrico Ammirati, Andreas Walter Kuss, Ana Tzvetkova, Wolfram C. Poller, Carsten Skurk, Arash Haghikia · 2023 · Journal of Clinical Medicine
  33. Familial Hypercholesterolemia in Children. The Current State of the Problem
    Dinara I. Sadykova, K. R. Salakhova, Л. Ф. Галимова, Е. С. Сластникова, Халиуллина Чулпан Данилевна · 2023 · Вопросы современной педиатрии
  34. Regulation of low-density lipoprotein on lipid metabolism in macrophages of large yellow croaker (Larimichthys crocea)
    Tingting Hao, Dan Xu, Xiufei Cao, Qiuchi Chen, Fan Chen, Qiangde Liu, Yuhang Tang, Yan Zhou, Yueru Li, Kangsen Mai et al. · 2023 · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
  35. Care Gaps and System Issues With Delivering Cardiovascular Risk Reduction and Lipid-Lowering Therapy in Secondary Prevention
    Guillaume Marquis‐Gravel, Sacha Bhatia, Vivien Brown, Shaun G. Goodman · 2024 · Canadian Journal of Cardiology
  36. From clinical development to real-world outcomes with inclisiran
    Derek Leslie Connolly, Vinoda Sharma, Kausik Kumar Ray · 2024 · Current Opinion in Lipidology
  37. Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future
    Marc Steven Sabatine, Ulrich Laufs · 2026 · European Heart Journal
  38. New Trends and Therapies for Familial Hypercholesterolemia
    Fahad Alnouri, Raul Dias Santos · 2022 · Journal of Clinical Medicine
  39. Familial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment
    Natalie Arnold, Wolfgang Köenig · 2023 · Reviews in Cardiovascular Medicine
  40. Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?
    Fistra Janrio Tandirerung · 2023 · Cardiovascular Drugs and Therapy
  41. Immune checkpoint inhibitors and myocardial infarction
    Vencel Juhász, Giselle Alexandra Suero‐Abreu, Tomas G. Neilan · 2025 · Journal of Thrombosis and Thrombolysis
  42. The Fomivirsen, Patisiran, and Givosiran Odyssey: How the Success Stories May Pave the Way for Future Clinical Translation of Nucleic Acid Drugs
    Mona Mansouri, Kimia Mansouri, Zahra Taheri, Samira Hossaini Alhashemi, Ali Dehshahri · 2025 · BioDrugs
  43. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects
    Daniel A. Duprez, Yehuda Handelsman, Michael J. Koren · 2020 · Vascular Health and Risk Management
  44. Dyslipidemia: Current Perspectives and Implications for Clinical Practice
    Sanja Klobučar Majanović, Olga Cvijanović, Dijana Detel, Gordana Kenđel Jovanović, Miro Bakula, Dario Rahelić, Tea Čaljkušić‐Mance, Tamara Šoić-Vranić, Sanja Zoričić Cvek · 2021 · IntechOpen eBooks
  45. Dyslipidemia: Current Therapies and Strategies to Overcome Barriers for Use
    Catherine DePhillips, Puja B. Parikh, Gregg Stevens · 2021 · The Journal for Nurse Practitioners
  46. 2022 Consensus statement on the management of familial hypercholesterolemia in Korea
    Chan Joo Lee, Minjae Yoon, Hyun‐Jae Kang, Byung Jin Kim, Sung Hee Choi, In‐Kyung Jeong, Sang‐Hak Lee, on behalf of Task Force Team for Familial Hypercholesterolemia, Korean Society of Lipid and Atherosclerosis · 2022 · The Korean Journal of Internal Medicine
  47. Non-Coding RNAs in Kidney Stones
    Guilin Wang, Jun Mi, Jiangtao Bai, Qiqi He, Xiaoran Li, Zhiping Wang · 2024 · Biomolecules
  48. Twice-yearly inclisiran injections halve LDL-cholesterol levels
    Irene Fernández-Ruíz · 2020 · Nature Reviews Cardiology
  49. Recent insights into low-density lipoprotein metabolism and therapy
    Angela Pirillo, Alberico Luigi Catapano, Giuseppe Danilo Norata · 2020 · Current Opinion in Clinical Nutrition & Metabolic Care
  50. Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine
    Nolwenn Tessier, Fatma Moawad, Nada Amri, Davide Brambilla, Catherine Martel · 2021 · Pharmaceutics
  51. Inclisiran in primary prevention: reality or fiction?
    Bariş Gencer, François Mach · 2022 · European Heart Journal
  52. Advances in familial hypercholesterolemia
    Martine Paquette, Alexis Wilfrid Baass · 2024 · Advances in clinical chemistry
  53. Silencing hepatic PCSK9 via novel chimeric AAV8 mitigates the progression of atherosclerosis by inhibiting inflammation in ApoE−/− mice
    Xiaocui Chen, Minghui Sun, Xiang Ma, Yitong Ma, Bang‐Dang Chen · 2024 · Molecular Therapy — Methods & Clinical Development
  54. Adverse events associated with inclisiran: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS)
    Li, Bing, Chen, Yan, Zhang, Yongyi, Qian, Mengying, Shan, Qing, Qian, Jiao, Guo, Jinmin · 2026 · Expert Opinion on Drug Safety
  55. Gene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation
    Evgeny E. Bezsonov, Nikita Chernyi, Mane Saruhanyan, Dariia Shimchenko, Nikolai Bondar, Darina Gavrilova, Mirza S. Baig, Alexander S. Malogolovkin · 2025 · International Journal of Molecular Sciences
  56. Phosphorothioate and 2′-Fluoro Ribose Substitution-Mediated Hydrophobic Effect Empowers RNA Probes for Highly Sensitive and Subtype-Selective miRNA Imaging
    Yingshun Zhou, Yuanyuan Fan, Hao Zhang, Qingqing Li, Haibin Si, Lu Li, Bo Tang · 2025 · ACS Nano
  57. Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial
    Albert Wiegman, Amy Lynn Hering Peterson, Éric Bruckert, Joep C. Defesche, Anja Schweizer, Jean Bergeron, María J Chueca, Jeanine E. Roeters van Lennep, Raul D. Santos, Karl Otfried Schwab et al. · 2026 · The Lancet Diabetes & Endocrinology
  58. Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease
    Philippe Gabríel Steg, Shaun G. Goodman, J. Wouter Jukema, Pieter Martens, Andreas Zirlik, Deepak L. Bhatt, Venu Menon, Michael J. Szarek, Anastasia Lesogor, Christian Stratz et al. · 2026 · American Heart Journal
  59. Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia
    Raechel T. White, Kjersten H. Sankey, James J. Nawarskas · 2023 · Cardiology in Review
  60. Familial Hypercholesterolemia: From Clinical Suspicion to Novel Treatments
    Saeid Mirzai, Parag Anilkumar Chevli, Rishi Raj Rikhi, Michael David Shapiro · 2023 · Reviews in Cardiovascular Medicine
  61. PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke
    Lin Zhou, Hongyu Zhang, Shuyi Wang, Hong Zhao, Yongnan Li, Juqian Han, Hongxu Zhang, Xiaoyuan Li, Zhengyi Qu · 2024 · Frontiers in Pharmacology
  62. Is there a role for earlier use of combination therapy?
    Shruti Revankar, Jong Kun Park, Priyanka Satish, Anandita Agarwala · 2024 · American Journal of Preventive Cardiology
  63. PEGylation Can Effectively Strike a Balance in siRNA Delivery Performances of Guanidinylated Linear Synthetic Polypeptides with Potential Use for Transcriptional Gene Silencing
    Xujun Lu, Jiajian Qiu, Yilan Li, Ming Cai, Xiaohan Yang, Suifei Li, Guodong Ye, Wei Yi, Yugang Huang · 2024 · ACS Macro Letters
  64. Inclisiran versus alirocumab in improving lipid profile parameters: A systematic review and meta‐analysis
    André Saad Cleto, João Matheus Schirlo, Victor Hugo Oliveira Gomes, Maria Luiza Julinhaque Beraldo, Guinter Sponholz Neiverth, Mayara Louise Beltrame, Janete Machozeki, Camila Marinelli Martins · 2024 · Diabetes Obesity and Metabolism
  65. Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis
    Lin Zhang, Bin Li, Wei Chen, Wei Li, Huayun Yang, Diguang Pan · 2025 · Reviews in Cardiovascular Medicine
  66. Current Evidence and Future Directions of PCSK9 Inhibition
    Jiaqian Xu, Michael David Shapiro · 2021 · US Cardiology Review
  67. Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII
    Patricia Recio-López, Ismael Valladolid‐Acebes, Philipp Hadwiger, Markus Hoßbach, Monika Krampert, Carla A. H. Prata, Per‐Olof Berggren, Lisa Juntti‐Berggren · 2022 · BioFactors
  68. Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease
    Christopher P. Kovach, Elise C. Mesenbring, Prerna Gupta, Thomas J. Glorioso, P. Michael Ho, Stephen W. Waldo, Gregory G. Schwartz · 2023 · JAMA Network Open
  69. Nucleic Acid Delivery Nanotechnologies for In Vivo Cell Programming
    Hannia V. Balcorta, Veronica Guerrero, Deepali Bisht, Wilson Poon · 2024 · ACS Applied Bio Materials
  70. Novel Therapeutic Approaches for the Management of Elevated Lipoprotein(a): From Traditional Agents to Future Treatment Options
    György Paragh, Péter Zilahi, László Róbert Kolozsvári, Hajnalka Lőrincz, Péter Fülöp, Mariann Harangi · 2024 · Life
  71. Impact of 12-SNP and 6-SNP Polygenic Scores on Predisposition to High LDL-Cholesterol Levels in Patients with Familial Hypercholesterolemia
    Giovanna Cardiero, Martina Ferrandino, Ilenia Lorenza Calcaterra, Gabriella Iannuzzo, Matteo Nicola Dario Di Minno, Raffaele Buganza, Ornella Guardamagna, Renata Auricchio, Maria Donata Di Taranto, Giuliana Fortunato · 2024 · Genes
  72. Analysis of Inclisiran in the US FDA Adverse Event Reporting System (FAERS): a focus on overall patient population and sex-specific subgroups
    YuBin He, Xin Guan, YaYun Zhang, Zixiong Zhu, YanHui Zhang, Yue Feng, Xuewen Li · 2024 · Expert Opinion on Drug Safety
  73. Cancer biology functional genomics: From small RNAs to big dreams
    Soumya Sundara Rajan, Katelyn R. Ludwig, Katherine L. Hall, Tamara L. Jones, Natasha J. Caplen · 2020 · Molecular Carcinogenesis
  74. Harnessing nucleic acid technologies for human health on earth and in space
    Samantha L. Sarli, Jonathan K. Watts · 2022 · Life Sciences in Space Research
  75. Cholesterol and alcohol
    Andrew S. Bell, Emma M. O’Connell, Falk W. Lohoff · 2022 · Elsevier eBooks
  76. Base Editing Gene Therapy for Heterozygous Familial Hypercholesterolemia
    Ping Wan, Siyuan Tang, Dongni Lin, Yuming Lu, Mei Long, Ling Xiao, Yanhong Jiang, Jiaoyang Liao, Xiaoying Ma, Ying Liu et al. · 2025 · medRxiv
  77. Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management
    Satyam, Shakta Mani, El-Tanani, Mohamed, Patni, Mohamed Anas, Rehman, Abdul, Irshad, Sara Muhammad, Raheem, Reem, Junais, Esha, John, Ashika Anu, Rassal, Rena Yusuf, Kumari, Rashmi et al. · 2026 · BMC Cardiovascular Disorders
  78. The Safety Profile of Inclisiran in Patients with Dyslipidemia: A Systematic Review and Meta-Analysis
    Maliha, Maisha, Satish, Vikyath, Kumar, Sriram Sunil, Chi, Kuan Yu, Shama, Nishat, Kharawala, Amrin, Duarte, Gustavo, Li, Weijia, Purkayastha, Sutopu, Mangeshkar, Shaunak et al. · 2025 · Healthcare
  79. “Inclisiran: Early LDL-C target achievement in a real-life population”
    Francesco Briani, Mauro Bagli, Gabriele Venturi, Francesco Bacchion, Antonio Mugnolo · 2025 · Atherosclerosis Plus
  80. Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates
    Saket Agarwal, Elizabeth Taft, Micah Gauthier, Justin Darcy, Kira Buckowing, Daniel Berman, Wendell P. Davis, Arlin B. Rogers, Maja M. Janas · 2025 · Nucleic Acid Therapeutics
  81. TGFBI R124H mutant allele silencing in granular corneal dystrophy type 2 using topical siRNA delivery
    Andrew McLain, Amanda M. Kowalczyk, Paulina Rachwalska, Flavia Maria Sutera, Louise J. Robertson, Nadia Sukusu Nielsen, Jan J. Enghild, Diego Cobice, Filippo Bonelli, Vanessa Barbaro et al. · 2025 · Journal of Controlled Release
  82. Small nucleic acid therapeutics: delivery breakthroughs, clinical translation, and future paradigms in precision medicine
    Yaqin Tang, Jie Zou, Qiyu Li, Yu Liu, Xiao Dong Guo, Huayang Bai, Xiao Dong He, Chunyuan Gan, Xia Zhao, Wen‐Li Wu et al. · 2025 · International Journal of Pharmaceutics
  83. Inclisiran in Patients with CKD
    Ulf Landmesser, Kausik Kumar Ray, Frederick Johan Raal, Lorena Garcia Conde, Jackie Han, Wolfgang Köenig, L. Leiter, Gregory G. Schwartz, R. Scott Wright, on behalf of the KCHF Study Investigators · 2026 · Journal of the American Society of Nephrology
  84. Advances in Analysis of Therapeutic Oligonucleotides with Chromatography Coupled to Mass Spectrometry
    Sandy Al Bardawil, Philippe Barthélémy, Ludivine Ferey · 2026 · Analytical Chemistry
  85. Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare
    A. I. Sapina, Yu. Yu. Varlamova, M. G. Papyrina, Alexey S. Bezymyanny, E. L. Kordzaya, E. Yu. Vasilyeva · 2024 · Russian Journal of Cardiology
  86. A Comparative Analysis of Low-Density Lipoprotein Cholesterol (LDL-C)-Lowering Activities of Bempedoic Acid, Inclisiran, and PCSK9 Inhibitors: A Systematic Review
    Yazhini Rajendran, Madhumita Nandhakumar, Madhavi Eerike, Nikhila Kondampati, Kalpana Ramanna Mali, Leo Francis Chalissery, Venu Gopala Rao Konda, Uma Maheswari Nagireddy · 2024 · Cureus
  87. Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?
    Nick S.R. Lan, Gerald Francis Watts · 2025 · Current Atherosclerosis Reports
  88. Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis
    Song Liu, Xingjin Wang, Jiaqiang Hu, Chen Zhao, Xiaoli Qin · 2025 · Diabetes Obesity and Metabolism
  89. Treatment of heterozygous familial hypercholesterolemia: what does the future hold?
    Georgios Polychronopoulos, Κωνσταντίνος Τζιόμαλος · 2020 · Expert Review of Clinical Pharmacology
  90. Can Clinicians Start Prescribing Inclisiran for Hypercholesterolemia Today? A Review of Clinical Studies for Internal Medicine Physicians and Endocrinologists
    Abdullah Jahangir, Syeda Sahra, Michael Krzyzak · 2021 · Cureus
  91. ▼Inclisiran: more hope less hype
    2022 · Drug and Therapeutics Bulletin
  92. Update on management of paediatric dyslipidaemia
    Nidhi Bansal, Seema Kumar, Preneet Cheema Brar · 2022 · Current Opinion in Endocrinology Diabetes and Obesity
  93. Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report
    Massimiliano Allevi, Silvia Sarnari, Federico Giulietti, Francesco Spannella, Chiara Di Pentima, Riccardo Sarzani · 2023 · Frontiers in Cardiovascular Medicine
  94. 2023 TAMIS/TSOC/TACVPR Consensus Statement for Patients with Acute Myocardial Infarction Rehabilitation.
    Kuan-Cheng Chen, Chih‐Neng Hsu, Cheng‐Hsueh Wu, Ko-Lung Lin, Shyh‐Ming Chen, Yu-Chun Lee, Chien‐Yi Hsu, Che‐Wei Hsu, Chi-Yao Huang, Shou-Hsien Huang et al. · 2023 · PubMed Central
  95. Lipid clinical trials with special reference to Indian population
    Aseem Basha M, Sivasubramanian Ramakrishnan · 2024 · Indian Heart Journal
  96. New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?
    Stephen James Nicholls, Adam J. Nelson · 2024 · Expert Opinion on Therapeutic Targets
  97. PCSK9 expression in fibrous cap possesses a marker for rupture in advanced plaque
    Yingying Zhang, Dongwei Dai, Shuang Geng, Chenbin Rong, Rong Zou, Xiaochang Leng, Jianping Xiang, Jianmin Liu, Jing Ding · 2024 · Vascular Medicine
  98. Long-term cardiovascular safety of inclisiran: a pooled analysis of phase 3 randomized trials
    Paschalis Karakasis, Dimitrios Patoulias, Fotios Barkas, Panagiotis Theofilis, Haralampos J. Milionis, Michael N. Doumas, George Kassimis, Konstantinos P Tsioufis, Nikolaos Fragakis · 2024 · Hellenic Journal of Cardiology
  99. Physician preferences for treatment of low-density lipoprotein cholesterol among patients with atherosclerotic cardiovascular disease (ASCVD)–A discrete choice experiment
    Marlon Graf, Amit V. Khera, Suepattra Grace May, Sukyung Chung, Laetitia N’Dri, Joaquim Rosado Cristino, Batul Electricwala · 2024 · Heliyon
  100. Cost-Effectiveness Analysis of Inclisiran for the Treatment of Primary Hypercholesterolemia or Mixed Dyslipidemia in Singapore
    Yan Ling Lim, Ru‐San Tan, Kian Keong Poh, Xiao Jun Wang · 2025 · Value in Health Regional Issues